The bumetanide it’s a commune diuretic pill to be administered orally which could be one potential candidate for Alzheimer’s disease treatment for those at genetic risk. This is stated by a study funded by the National Institute on Aging (NIA), part of the National Institutes of Health, which showed that those who took the drug had a significantly lower prevalence of Alzheimer’s disease than those who did not.
Bumetanide is a strong diuretic used to treat edema (fluid retention, excess fluid retained in body tissues) caused by various medical problems, including heart, kidney, and liver disease and works by causing the kidneys to get rid of unnecessary water and salt from the body in the urine.
Being a very powerful drug it can cause dehydration and other serious side effects, so when taking it, it is important to follow your doctor’s prescriptions in detail.
Dosage is based on medical conditions and response to treatment. Older adults usually start with a lower dose to reduce the risk of unwanted side effects.
The Education have been published in the scientific journal Nature Aging.
Bumetanide and Alzheimer’s: this is what the research says
The research team analyzed the information in the databases of brain tissue samples and FDA-approved drugs and performed experiments in both mice and human cells and explored human population studies to identify bumetanide as a leading drug candidate that could potentially be repurposed to treat Alzheimer’s.
“Although further testing and clinical trials are needed, this research underscores the value of large data-driven tactics combined with more traditional scientific approaches to identify existing drug-approved drugs. FDA as candidates for reuse drugs to treat Alzheimer’s disease “, has explained Richard J. Hodes, scientist who participated in the research.
Knowing that one of the most significant genetic risk factors for late-onset Alzheimer’s is a form of the apolipoprotein E gene called APOE4, The researchers analyzed data from 213 brain tissue samples and identified signatures of Alzheimer’s gene expression, the levels at which genes are turned on or off, specific to APOE4 vectors.
Subsequently, they have compared APOE4-specific Alzheimer’s signatures to those of more than 1,300 known FDA-approved drugs. Five drugs with a gene expression signature emerged that the researchers believed could help neutralize the disease. The strongest candidate was bumetanide, which is used to treat fluid retention often caused by medical problems such as heart, kidney and liver disease.
Researchers validated the data-driven findings by testing bumetanide in both mouse models of Alzheimer’s and human neuron-derived pluripotent stem cells. The researchers found that treating mice that expressed the human APOE4 gene reduced learning and memory deficits. The neutralizing effects were also confirmed in human cell-based models, which led to the hypothesis that people already taking bumetanide should have lower rates of Alzheimer’s.
To test this insight, the team divided electronic health record data sets from more than 5 million people into two groups: adults over 65 who took bumetanide and a corresponding group who did not take bumetanide. The analysis showed that those who had the genetic risk and took bumetanide had a 35 to 75% lower prevalence of Alzheimer’s disease than those who did not take the therapy.
“We know that Alzheimer’s disease will likely require specific types of treatments, perhaps multiple therapies, including some that can target an individual’s unique genetic and pathological characteristics, just like the cancer treatments that are available today.i, ”he said Jean Yuan, MD, Ph.D., Director of the Translational Bioinformatics and Drug Development Program in the NIA’s Division of Neuroscience. “The data in this document constitute a good case for conducting a bumetanide test in people with genetic risk ”.
The research team was led by scientists from the Gladstone Institutes, San Francisco, the University of California, San Francisco, and the Icahn School of Medicine in Mount Sinai, New York City.